Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as the company saw its shares rise by roughly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 72% in the past one-month time frame.
This biotechnology company has seen four negative revisions over the last 30 days and its Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Merrimack Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked bio-med stocks include Actelion Ltd. (ALIOF), AMAG Pharmaceuticals, Inc. (AMAG) and Heska Corporation (HSKA). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
MERRIMACK PHARMACEUTICALS INC (MACK): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
AMAG PHARMACEUTICALS INC (AMAG): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
Zacks Investment Research